The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Findings from a MAIC of BVd versus KRd in second-line myeloma treatment
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the findings of a matching-adjusted indirect comparison (MAIC) of belantamab mafidotin, bortezomib, and dexamethasone (BVd) versus carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma (R/R MM). Dr Ramasamy highlights that BVd shows superior progression-free survival (PFS) in this patient population, and this analysis shows a clinical benefit for choosing BVd over KRd in the second-line setting, particularly in lenalidomide-naive patients. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we’ve done a matched, adjusted, indirect comparison because there is no clinical trial which compares belantamab mafodotin, bortezomib, dexamethasone versus carfilzomib, lenalidomide and dexamethasone. But the reason to do this matched, adjusted, indirect comparison is in the UK, carfilzomib, lenalidomide, and dexamethasone is still a second line option for patients...
So we’ve done a matched, adjusted, indirect comparison because there is no clinical trial which compares belantamab mafodotin, bortezomib, dexamethasone versus carfilzomib, lenalidomide and dexamethasone. But the reason to do this matched, adjusted, indirect comparison is in the UK, carfilzomib, lenalidomide, and dexamethasone is still a second line option for patients. And because belantamab, bortezomib, dexamethasone is approved for patients who are lenalidomide naive who could also get KRd, this analysis was specifically done to show whether the efficacy of belantamab mafodotin, bortezomib, dexamethasone was superior to carfilzomib, lenalidomide, and dexamethasone. And in this matched adjusted indirect comparison, we show that patients receiving belantamab mafodotin, bortezomib, dexamethasone matched for all the clinical parameters show a superior progression-free survival in this patient population. So this clearly shows a clinical benefit for patients to choose belantamab mafodotin, bortezomib, dexamethasone in the second-line setting over the currently available KRd treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
